Since the FDA approval of the CTLA-4 antibody ipilimumab in 2011 for the treatment of advanced melanoma, several antibodies targeting CTLA-4, PD-1, and PD-L1 have been approved for various cancers. The gene discussed is CTLA4; the disease is melanoma.